Rituximab therapy in autoimmune pulmonary alveolar proteinosis.
Idiopathic pulmonary alveolar proteinosis is presumed to be an autoimmune disorder that may lead to pulmonary insufficiency. However, steroids do not appear to be effective and the standard of therapy is whole-lung lavage. We report the first case of successful therapy with rituximab, which addresses the pathogenic mechanism of pulmonary alveolar proteinosis.
Borie
R
R
Service de Pneumologie A, Faculté de médecine Denis Diderot, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Université Paris 7, Paris, France. raphael.borie@bch.aphp.fr
Debray
M-P
MP
Laine
C
C
Aubier
M
M
Crestani
B
B
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D001327:Autoimmune Diseases / Q000175:diagnosis / Q000188:drug therapy*; D001706:Biopsy; D018893:Bronchoalveolar Lavage; D003937:Diagnosis, Differential; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D011649:Pulmonary Alveolar Proteinosis / Q000175:diagnosis / Q000188:drug therapy*; D012129:Respiratory Function Tests; D000069283:Rituximab; D014057:Tomography, X-Ray Computed
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab